Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
It promises fewer injections for vision loss patients
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The facility features 2,176 high-performance GPUs across the US and Europe
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Subscribe To Our Newsletter & Stay Updated
